Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Conditions
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Grade 3b Follicular Lymphoma
- Recurrent High Grade B-Cell Lymphoma
- Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Recurrent Transformed Chronic Lymphocytic Leukemia
- Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Grade 3b Follicular Lymphoma
- Refractory High Grade B-Cell Lymphoma
- Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Refractory Transformed Chronic Lymphocytic Leukemia
- Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
- PROCEDURE: Biopsy
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Computed Tomography
- BIOLOGICAL: Loncastuximab Tesirine
- BIOLOGICAL: Mosunetuzumab
- PROCEDURE: Positron Emission Tomography
Sponsor
City of Hope Medical Center
Collaborators